AP
Men who took low doses of the drug for a year cut their chances of developing prostate cancer roughly in half, doctors reported Saturday at meeting of the American Society of Clinical Oncology.
The findings need to be tested in larger studies, specialists say. But this is the first time any drug has been shown to prevent a precancerous condition from forming a tumor.
More...
|